Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Assets (2016 - 2026)

Cumberland Pharmaceuticals' Assets history spans 16 years, with the latest figure at $76.8 million for Q4 2025.

  • On a quarterly basis, Assets rose 1.64% to $76.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $76.8 million, a 1.64% increase, with the full-year FY2025 number at $76.8 million, up 1.64% from a year prior.
  • Assets hit $76.8 million in Q4 2025 for Cumberland Pharmaceuticals, up from $65.9 million in the prior quarter.
  • Over the last five years, Assets for CPIX hit a ceiling of $96.7 million in Q1 2022 and a floor of $65.9 million in Q3 2025.
  • Historically, Assets has averaged $83.4 million across 5 years, with a median of $86.0 million in 2021.
  • Biggest five-year swings in Assets: grew 10.02% in 2022 and later fell 14.2% in 2025.
  • Tracing CPIX's Assets over 5 years: stood at $84.5 million in 2021, then grew by 10.02% to $92.9 million in 2022, then fell by 12.0% to $81.8 million in 2023, then dropped by 7.57% to $75.6 million in 2024, then increased by 1.64% to $76.8 million in 2025.
  • Business Quant data shows Assets for CPIX at $76.8 million in Q4 2025, $65.9 million in Q3 2025, and $67.9 million in Q2 2025.